Follow the people · Insider
Nicholas A.J. Botwood
Nicholas A.J. Botwood files insider transactions with the SEC as a head of r&d, cmo of Syndax Pharmaceuticals (SNDX). We hold 2 disclosed purchases and sales filed since 19 May 2025, 2 of them in the last 90 days.
- Files forSNDX
- Disclosed buys and sells2 in all, 2 in the last 90 days
- Last disclosure12 June 2026
Positions held
1 post we hold — a term names its own dates; a run of filings only says when they filed- Filed 16 May 2025 — 12 June 2026Head of R&D, CMO · Syndax Pharmaceuticals (SNDX)13 Form 4 lines · source: SEC Form 4
Everything they disclosed
13 entries, newest first — one per disclosure report, one per Form 4 line- exercised options over 22,515 shares of Syndax PharmaceuticalsSEC Form 412 June 2026Common Stock · traded 11 June 2026 · filed 12 June 2026
- ▼ sold on the open market 34,280 shares of Syndax PharmaceuticalsSEC Form 412 June 2026Common Stock · traded 11 June 2026 · filed 12 June 2026
- exercised options over 31,235 shares of Syndax PharmaceuticalsSEC Form 412 June 2026Common Stock · traded 12 June 2026 · filed 12 June 2026
- ▼ sold on the open market 31,235 shares of Syndax PharmaceuticalsSEC Form 412 June 2026Common Stock · traded 12 June 2026 · filed 12 June 2026
- exercised options over 22,515 shares of Syndax Pharmaceuticals (a derivative holding)SEC Form 412 June 2026Stock options (Right to buy) · traded 11 June 2026 · filed 12 June 2026
- exercised options over 31,235 shares of Syndax Pharmaceuticals (a derivative holding)SEC Form 412 June 2026Stock options (Right to buy) · traded 12 June 2026 · filed 12 June 2026
- was granted 24,000 shares of Syndax PharmaceuticalsSEC Form 46 February 2026Common Stock · traded 4 February 2026 · filed 6 February 2026
- was granted 36,000 shares of Syndax PharmaceuticalsSEC Form 46 February 2026Common Stock · traded 4 February 2026 · filed 6 February 2026
- was granted 144,700 shares of Syndax Pharmaceuticals (a derivative holding)SEC Form 46 February 2026Stock Options (Right to buy) · traded 4 February 2026 · filed 6 February 2026
- was granted 144,700 shares of Syndax Pharmaceuticals (a derivative holding)SEC Form 46 February 2026Stock Options (Right to buy) · traded 4 February 2026 · filed 6 February 2026
- was granted 24,000 shares of Syndax PharmaceuticalsSEC Form 46 February 2026Common Stock · traded 4 February 2026 · filed 6 February 2026
- was granted 36,000 shares of Syndax PharmaceuticalsSEC Form 46 February 2026Common Stock · traded 4 February 2026 · filed 6 February 2026
- ▲ bought on the open market 11,765 shares of Syndax PharmaceuticalsSEC Form 419 May 2025Common Stock · traded 16 May 2025 · filed 19 May 2025
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.